List view / Grid view

News

More needs to be done in cancer prevention and detection suggests report

19 May 2017 | By Sarah Wills, Editorial Assistant: European Pharmaceutical Review

While there have been improvements in some areas of cancer prevention and early detection, the use of potentially lifesaving measures is suboptimal and strongly influenced by individual behaviours, as well as social, economic, and public policy factors, according to a new report from the American Cancer Society.

A strong EU IP framework guarantees future innovation for patients

19 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)

Intellectual Property (IP) could be considered the foundation for pharmaceutical innovation. In healthcare, innovation means improved health outcomes: avoiding illness; slowing disease progression; improving patients’ lives; and reducing overall costs for healthcare systems. With over 80 medicines approved every year – including some 30 new, approved substances – and over…

Nanoscale diamond ‘racetrack’ becomes breakthrough Raman laser

18 May 2017 | By The Optical Society

Diamonds are renowned for their exquisite beauty and unrivalled durability, but they also are highly prized by scientists and engineers for their exceptional optical and physical properties. In a first-of-its-kind demonstration of diamond’s promising technological applications, a team of engineers from Harvard University has developed a new class of Raman…

Raman scattering for non-invasive prostate cancer screening

18 May 2017 | By American Institute of Physics (AIP)

Cancer screening is a critical approach for preventing cancer deaths because cases caught early are often more treatable. But while there are already existing ways to screen for different types of cancer, there is a great need for even more safe, cheap and effective methods to save even more lives.…

Enzyme Indicators – New technology for decontamination validation

18 May 2017 | By Phillip Godden, CEO, Protak Scientific

Enzyme Indicators (EI’s) are an industry-changing advance in measuring decontamination performance. No longer will the pharmaceutical industry suffer financial losses, wasted man hours, and the burden of high risks associated with BI’s.